Lessening Organ Dysfunction With VITamin C in Septic ARDS — LOVIT ARDS  

Acute Respiratory Distress Syndrome Clinical Trial

Official title: A Multicentre Concealed-Allocation Parallel-Group Blinded Randomized Controlled Trial to Ascertain the Effect of High-Dose Intravenous Vitamin C Compared to Placebo on Mortality or Persistent Organ Dysfunction at 28 Days in Septic Intensive Care Unit Patients

Status Recruiting

Clinical Trial Summary

The primary objective of the study aims to compare the effect of high-dose intravenous vitamin C vs. placebo on a composite of death or persistent organ dysfunction - defined as continued dependency on mechanical ventilation, new renal replacement therapy, or vasopressors - assessed at 28 days on intensive care unit (ICU) patients.

As secondary objectives, the study aims:

• To compare the effect of high-dose intravenous vitamin C vs. placebo on:

1. 6-month mortality;

2. 6-month HRQoL;

3. organ function (days 1, 2, 3, 4, 7, 10, 14, and 28 if in ICU);

4. global tissue dysoxia (at baseline);

5. oxygenation Index (FiO2 x Mean Airway Pressure/PaO2) (days 1, 2, 3, 4, 7, 10, 14, and 28 if in ICU, and if still intubated);

6. occurrence of stage 3 acute kidney injury as defined by KDIGO (Kidney Disease:

Improving Global Outcomes) criteria20;

7. acute hemolysis as defined by:

• clinician judgment of hemolysis, as recorded in the chart, or

• hemoglobin drop of at least 25 g/L within 24 hours of a dose of investigational product PLUS 2 of the following:

• reticulocyte count >2 times upper limit of normal at clinical site lab;

• haptoglobin < lower limit of normal at clinical site lab;

• indirect (unconjugated) bilirubin >2 times upper limit of normal at clinical site lab;

• lactate dehydrogenase (LDH) >2 times upper limit of normal at clinical site lab.

Severe hemolysis:

• hemoglobin < 75 g/L AND at least 2 of the above criteria AND requires 2 units of packed red blood cells;

8. hypoglycemia as defined as core lab-validated glucose levels of less than < 3.8 mmol/L.

• To assess baseline vitamin C levels in study participants (before the first dose of investigational product).

Clinical Trial Description

Treatment options for sepsis complicated by ARDS are limited to antimicrobials and supportive care (intravenous fluids, vasopressors, mechanical ventilation and renal replacement therapy). Recent preliminary evidence suggests that intravenous vitamin C may be the first therapy to mitigate the dysregulated cascade of events transforming an infection into sepsis. However, definitive practice changing evidence requires a large trial powered to detect a plausible, modest, and clinically important difference in mortality.

The study LOVIT will be conducted simultaneously in Canada (country of coordination), France, the United States of America, the United Kingdom and Australia/New Zealand.The data from each country will be merged with the aim of reaching 4,000 patients globally (roughly 800 patients per country). Thus, in the context of increasing off-label use of vitamin C for sepsis and ongoing trials of vitamin C bundled with other pharmacological interventions, this study will constitute a rigorous assessment of the effect of vitamin C monotherapy on patient-important outcomes. Moreover, the French LOVIT-ARDS, part of LOVIT, will provide additional information on the specific subgroup of patients with sepsis and ARDS.

This is a prospective multicentric randomized controlled trial. Web-based randomization system available 24/7. Eligible patients will be randomized in a 1:1 ratio to vitamin C or matching placebo. The study will use permuted blocks of undisclosed and variable size and stratify randomization by site.

The study will enroll a total of at least 770 patients. Sites are expected to enroll at least 1or 2 patients per month. By enrolling 385 evaluable patients per arm, the study will have 80% power to detect a 10% absolute risk reduction (from 50% to 40%, which corresponds to a 20% relative risk reduction).

Follow-up in the study for each patient: daily during ICU stay and telephone follow-up at 6 months. ;

Related Conditions & MeSH terms

• Acute Lung Injury
• Acute Respiratory Distress Syndrome
• Respiratory Distress Syndrome
• Respiratory Distress Syndrome, Newborn
• Septic

• NCT number: NCT04404387
• Study type: Interventional
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: Djillali ANNANE, MD, PhD
• Phone: +33 1 47 10 77 87
• Email: djillali.annane@aphp.fr
• Status: Recruiting
• Phase: Phase 3
• Start date: July 22, 2022
• Completion date: July 2024